Dexamethasone Dose in Low Volume Bupivacaine USG Supraclavicular Block

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-01

Study Completion Date

2018-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A dose-ranging study to test various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an adjuvant to Local anesthetic drugs in ultrasound guided low volume Supraclavicular brachial plexus block to find the best balance between valuable effects (mainly duration of analgesic Effect) and side-effects (mainly increased random blood sugar levels)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Peri-neural Dexmedetomidine Versus Dexamethasone for Supraaclavicular Block Adjuvant to Bupivacaine Supraclavicular Brachial Plexus Block

NCT04694105

Brachial Plexus Block

COMPLETED NA

Ketamine Versus Dexmedetomidine in Supraclavicular Brachial Plexus Block

NCT04508894

Supraclavicular Brachial Plexus Block

COMPLETED NA

Infraclavicular Brachial Plexus Block With Bupivacaine Alone or With Both Dexmedetomidine and Dexamethasone

NCT06356415

Upper Extremity Injury

NOT_YET_RECRUITING NA

Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block

NCT01538459

Shoulder Pain Injury of Shoulder Region Disorder of Shoulder +2 more

WITHDRAWN PHASE3

Dexamethasone Versus Nalbuphine as Adjuvants in Brachial Plexus Block

NCT04194320

Anesthesia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Brachial plexus nerve blocks (BPBs) for upper extremity surgery provide superior analgesia and reduce opioid consumption. Supraclavicular block anesthetizes the brachial plexus where it is in its most compact form, thus providing a complete and reliable block for upper extremity surgery. Ultrasound guided single injection (SI) and triple injection (TI) techniques were found to provide the same degree of surgical anesthesia at 30 minutes while the TI technique needed more time to perform.

Many studies were conducted to examine the effect of perineural Dexamethasone as a local anesthetic adjuvant in low volume peripheral nerve blocks were it was found to increase the mean duration of analgesia (sensory block) with short, medium and long acting local anesthetics as well as the duration of motor blockade, with a reduction in pain scores at rest during the intermediate (8-12 h) and late (24 h) postoperative periods and in movement at all times. At 24 postoperative hours, cumulative morphine consumption and the rate of nausea or vomiting were also reduced without any reported related serious adverse effects, also the value of its concomitant intravenous use in prolonging the duration of analgesia after regional blocks was studied with promising results that can sometimes be compared to the perineural route but more short-lived and associated with higher increase in blood glucose levels. Dexamethasone's mechanism of action may result from decreased nociceptive C-fibre activity via a direct effect on glucocorticoid receptors and inhibitory effect on potassium channels.(8) Other authors suggest a local vasoconstrictive effect, resulting in reduced local anaesthetic absorption or a systemic anti-inflammatory effect following vascular uptake of the drug.

A debate exists whether perineural corticosteroids are harmful or not, but reports of neurotoxicity seem to be related mainly to the preservative benzyl alcohol and the vehicle polyethylene glycol found in some preparations, also may be related to the presence of insoluble steroid particulate matter in the injectate. Dexamethasone is non-particulate and can be found in a preservative-free formulation. In addition, no significant long-term electrophysiological, behavioural or histological effects for corticosteroids were identified on rat sciatic nerve tissue even some data suggest dexamethasone may actually be neuroprotective. In reality, perineural corticosteroid injections with and without preservative are widely used throughout the world.

Various doses of Dexamethasone were used in local anaesthetic mixtures in regional blocks in various studies, including 4, 5, 8 and 10 mg. In a recent review \& meta-analysis by E. Albrecht and his colleagues, sub-group analysis revealed no association between the total dose of perineural Dexamethasone and the mean increase in duration of analgesia showing that Dose-finding studies are needed to better define the optimal balance between dose, effects and side-effects, particularly at doses lower than 4 mg.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dexamethasone Supraclavicular Brachial Plexus Block

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The patients will be randomized to 4 groups:

* Group A: N-12 will receive a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.
* Group B: N-12 will receive a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.
* Group C: N-12 will receive a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.
* Group Control: N-12 will receive a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

The patient and the attending anesthetist who will manage the patient intra-operatively and perform the block, will be blinded to the patient group allocation All recorded values will be obtained by personnel blinded to the group allocation of the patient.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.

Group Type ACTIVE_COMPARATOR

Ultrasound guided supraclavicular brachial plexus block

Intervention Type PROCEDURE

ultrasound guided Supraclavicular brachial plexus block

Dexamethasone

Intervention Type DRUG

Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs

Group B

N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.

Group Type ACTIVE_COMPARATOR

Ultrasound guided supraclavicular brachial plexus block

Intervention Type PROCEDURE

ultrasound guided Supraclavicular brachial plexus block

Dexamethasone

Intervention Type DRUG

Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs

Group C

N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.

Group Type ACTIVE_COMPARATOR

Ultrasound guided supraclavicular brachial plexus block

Intervention Type PROCEDURE

ultrasound guided Supraclavicular brachial plexus block

Dexamethasone

Intervention Type DRUG

Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs

Group Control

N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline.

Group Type ACTIVE_COMPARATOR

Ultrasound guided supraclavicular brachial plexus block

Intervention Type PROCEDURE

ultrasound guided Supraclavicular brachial plexus block

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultrasound guided supraclavicular brachial plexus block

ultrasound guided Supraclavicular brachial plexus block

Intervention Type PROCEDURE

Dexamethasone

Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Decadron

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing surgeries in the upper limb (arm, forearm or hand)

Exclusion Criteria

* Coagulopathies (with prothrombin concentration less than 60% or INR more than 1.5)
* In-ability to postpone anti-coagulation medications.
* Infection or injury or a lesion at the block site.
* Suspected cervical vertebral column injury necessitating using a neck collar.
* A compromised lung on the contralateral side of the block (Pneumothorax, hemothorax or Pneumonectomy).
* Traumatic vascular injuries or operative interventions (Surgical harvesting) involving arteries of the upper limb on the operative side.
* Patients with communication difficulties.
* Hypersensitivity to local anesthetics and/or Dexamethasone.
* Patients on perioperative intravenous (IV) steroids.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No